Xu Liu1†
Xiangqi Kong
Xu Chen- 1Department of Psychiatry, Shandong Daizhuang Hospital, Jining, China
- 2Department of Psychiatry, School of Mental Health, Jining Medical College, Jining, Shandong, China
- 3Department Substance Abuse, Shandong Mental Health Center, Shandong University, Jinan, Shandong, China
- 4Department of Psychiatry, Jining Medical College, Jining, Shandong, China
Objective: Patients with Alcohol Use Disorder (AUD) often experience significant mood disturbances and sleep disorders during the acute withdrawal period. This study aims to assess the sleep quality of AUD patients during acute withdrawal using polysomnography (PSG) and to evaluate their emotional states through standardized scales, to explore the role these factors play in the sleep quality of AUD patients during the acute withdrawal period.
Methods: The study’s experimental group consisted of fifty male patients, aged 18 to 66. Fifty healthy male volunteers served as the control group. On days 1–2 of alcohol withdrawal, PSG evaluated sleep processes, structural characteristics, and sleep-related breathing parameters in both AUD patients and the control group. The Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Penn Alcohol Craving Scale (PACS), and Barratt Impulsiveness Scale (BIS) were used to measure impulsivity, mood disorders, alcohol desire, and sleep quality, respectively. The use of multiple linear regression to analyze factors related to sleep disorders.
Results: Compared to the control group, AUD patients exhibited significantly reduced total sleep time, sleep efficiency, and rapid eye movement (REM) sleep, along with increased snoring frequency and duration. Additionally, AUD patients had significantly higher scores on the PACS, BDI, and BAI. Multiple regression analysis revealed that alcohol craving, depression, and anxiety were significantly associated with impaired sleep quality.
Conclusion: Our findings demonstrate that AUD patients experience significant sleep disturbances during the acute withdrawal period, influenced by alcohol craving, depression, and anxiety.
1 Introduction
Alcohol is both a neurotoxin and a central nervous system depressant (1). Excessive intake leads to multi-system damage in the human body (2–5). The core characteristics of AUD include heavy drinking and an inability to control alcohol intake (6), making it a global public health issue responsible for approximately 3 million deaths annually (7). Compared to healthy non-drinkers, AUD patients face more severe sleep and mood problems (8–10). Emotional regulation disorders are key factors driving continued alcohol consumption in AUD patients (11), increasing their risk of relapse when facing negative emotions.
The acute withdrawal period for AUD refers to the hours to days following the last drink (12). During this time, patients may experience symptoms including nausea, tachycardia, hypertension, anxiety, and insomnia (13–15), collectively known as Alcohol Withdrawal Syndrome (AWS). The severity of AWS typically correlates with the degree of alcohol dependence and the duration of alcohol abuse. A systematic review shows symptoms are most severe in the first 2–3 days of acute withdrawal and improve over time (16, 17). We chose to observe patients during the first 1–2 days to better understand the impact of withdrawal on mood and sleep, providing early insights for clinical intervention. Biological processes such as reactive oxygen species (ROS) generation, protein kinase activation, mitochondrial integrity damage, and changes in inflammatory factor levels are critical during alcohol withdrawal (18).
Previous studies have shown that alcohol withdrawal can trigger mood disorders (19), with significant comorbidity between alcohol withdrawal and mood disorders, particularly anxiety and depression. Withdrawal symptoms are closely linked to alcohol craving, emotional disturbances (such as anxiety and depression) (20), and sleep disorders (21), making these factors useful indirect indicators of withdrawal severity. A study on Eastern European populations found a strong association between alcohol withdrawal, drinking, and the occurrence of depressive symptoms (22). Rodent models of alcohol dependence have also demonstrated physical and emotional symptom changes during alcohol withdrawal (23–25). Forced abstinence (FA) in animal models induces anxiety- and depression-like symptoms (26). Six hours after alcohol withdrawal, rats exhibited symptoms such as hyperactivity, agitation, stereotypic behavior, tail stiffness, abnormal gait and posture, and audiogenic seizures (27). However, some studies indicate that depression-like behaviors typically emerge after a longer period of alcohol withdrawal (e.g., 2 weeks) rather than during the acute withdrawal phase. This may be due to the neuroadaptive changes caused by prolonged alcohol consumption, with the central nervous system still recovering during the acute withdrawal phase, leading to unstable emotional states that may later manifest as mood disorders. Sudden cessation of alcohol intake triggers acute central nervous system (CNS) inflammatory responses in key brain regions regulating autonomic and emotional states, affecting mood (28). In alcohol-withdrawn mice, increased expression of kynurenine (KYN), decreased expression of 5-hydroxytryptamine (5-HT), and abnormal expression of 3-hydroxykynurenine (3-HK) and kynurenic acid (KA) were observed in the hippocampus, cerebral cortex, and amygdala, all of which play important roles in mood regulation (29).
Sleep disorders may occur at various stages of AUD, including during long-term drinking and alcohol withdrawal periods (30–33). Heavy drinking can lead to insomnia, and insomnia symptoms may increase the risk of future alcohol consumption (34). These changes are potentially linked to decreased dopamine function and overactivation of stress neuromodulators caused by prolonged heavy drinking (35). A follow-up study of patients abstinent from alcohol for 13 years found a higher incidence of insomnia during the acute withdrawal phase compared to the drinking period (36). Compared to healthy controls, moderate AWS patients exhibit changes in non-rapid eye movement (NREM) sleep, widespread gray matter shrinkage, and cognitive performance decline (37).
Despite the existing literature on alcohol withdrawal and its associated mood and sleep disorders, this study aims to provide further analysis using PSG, combined with patient history, medication use, and sleep laboratory observations, to leverage more objective physiological parameters (38). PSG is recognized as the gold standard for evaluating and diagnosing sleep-related breathing disorders (39). It comprehensively analyzes electroencephalogram, electrooculogram, electromyogram, electrocardiogram, pulse oximetry, airflow, and respiration data to assess the underlying causes of sleep disorders. PSG can monitor arousal, sleep architecture (sleep stage distribution), and arousal frequency (40), and it is also used to assess other sleep disorders such as narcolepsy (41). Studies have found that AUD patients during the acute withdrawal period exhibit sleep abnormalities, including increased sleep latency and fragmentation, reduced sleep duration and efficiency, and a decreased percentage of NREM stage 3 sleep (N3) (42). Reduced slow-wave sleep during this phase, along with limited REM sleep recovery, may be related to the positive allosteric modulation of Gamma-aminobutyric acid type A (GABAA) receptors by alcohol and other mechanisms (43). Reduced REM sleep time has significant implications for mood regulation and sleep quality (44–46). In AUD patients during acute withdrawal, reduced REM sleep may exacerbate mood problems and sleep disorders, potentially creating a negative feedback loop that further affects withdrawal outcomes and long-term recovery. By analyzing the objective differences in sleep quality during the acute withdrawal period in AUD patients, combined with subjective assessments from patient scales, this study aims to further explore the factors influencing sleep during the acute withdrawal period of alcohol use disorder.
2 Materials and methods
2.1 Study subjects
Patients were screened according to the DSM-5 criteria for AUD, including those diagnosed with alcoholism or alcohol dependence. Due to the requirement for scale assessments and complete PSG monitoring, we selected patients aged 18 to 66 years who could independently complete both the PSG monitoring and scale assessments. The study included male AUD patients newly admitted between December 2021 and December 2022. Out of an initial 287 patients, those with severe neurodevelopmental disorders, neuropsychiatric diseases, or neurological conditions were excluded.
Additionally, patients who had used any antidepressants or antipsychotics in the past two weeks or had a history of other substance dependencies or abuse (excluding tobacco) were also excluded. This was to minimize the potential impact of these substances on the study outcomes. Research has shown that antidepressants and antipsychotic medications can alter mood, sleep architecture, and neurobiological responses, with different drugs having varying effects (47–50). Similarly, other substance dependencies can affect mood and sleep structures (51, 52). Ultimately, 50 eligible male AUD patients were selected for analysis, along with 50 healthy non-drinking males as a control group.
All procedures adhered to the ethical principles outlined in the 1964 Declaration of Helsinki and received approval from the institutional bioethics committee. Informed consent was obtained from all participants.
2.2 Sleep and mood assessments
Anxiety symptoms were assessed using the BAI (53), a 21-item self-report questionnaire with scores ranging from 0 to 3 per item, and a total score of 63. Scores above 45 indicate significant anxiety symptoms. Depression severity was assessed using the BDI (54), also a 21-item questionnaire with total scores ranging from 0 to 63. Depression severity is categorized as minimal or no depression (0–4), mild (5–13), moderate (14–20), and severe (21 and above). Impulsiveness was evaluated using the BIS (55), a 30-item questionnaire scored on a scale of 1 to 4, with higher scores indicating greater impulsiveness.
Alcohol craving severity was measured using the PACS (56), which assesses the frequency, intensity, and duration of cravings, the ability to resist cravings, and the average craving level over the past week, on a scale of 0 to 6. Higher scores indicate more severe cravings. Sleep quality was evaluated using the PSQI (57), an 18-item questionnaire covering seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each item is scored from 0 to 3, with a total score of 21. Scores above 7 indicate poor sleep quality. The study group completed these assessments on the 7th-8th day post-enrollment, while the control group completed them on the 1st-2nd day post-enrollment along with sleep monitoring.
2.3 Polysomnography monitoring
Data collection and analysis were conducted using the Compumedics Greal PSG 48-channel system. Both the study and control groups underwent PSG assessments on the 1st-2nd day post-enrollment to evaluate sleep processes and structural parameters. Monitored indices included total sleep time (TST), durations of deep and light sleep, REM latency, percentage of REM sleep, apnea-hypopnea index (AHI), number of apnea and hypopnea events, average heart rate, snoring frequency, awakenings, snoring time, average oxygen saturation, and lowest oxygen saturation. These metrics effectively capture changes in sleep structure and physiological baseline data (40).
Both groups underwent consecutive two-night monitoring in a sleep center with controlled ambient conditions (temperature: 18-25°C, relative humidity: 50%-60%). Monitoring occurred from 22:00 to 06:00. Subjects with recordings shorter than 6 hours were re-monitored the next night to eliminate the first-night effect (58). Two professional sleep technicians analyzed the data for all subjects.
2.4 Statistical analysis
Data were compiled using Excel 2007 and analyzed with SPSS 26.0. The Shapiro-Wilk and Kolmogorov-Smirnov tests assessed the normality of continuous variables. For normally distributed parameters, independent sample t-tests compared groups, with data presented as mean ± standard deviation. Non-normally distributed parameters were compared using the Mann-Whitney U test, with data presented as median and interquartile range [M (P25, P75)]. Chi-square tests analyzed categorical variables, presented as percentages (rates), with inter-group comparisons using χ² tests. Multiple linear regression analyzed related influencing factors, with statistical significance set at p < 0.05.
2.5 Quality control
To ensure the smooth and efficient conduct of the study, rigorous quality control measures were implemented. The project leader provided comprehensive training for researchers on inclusion and exclusion criteria, scale scoring rules, and standardized instructions before the study commenced. All PSG monitoring was conducted in the sleep center, with results analyzed by two professional sleep technicians. Attending physicians evaluated patients for comorbidities or other conditions, excluding those who did not meet the criteria to maintain data integrity. Data entry employed double-entry methods, with 10% of patients randomly selected for consistency checks by two attending or higher-level physicians. Unqualified subjects were excluded to ensure data reliability.
3 Results
3.1 General characteristics analysis
This study included a total of 100 participants who met the research criteria. The study group comprised 50 males with an age range of 18 to 66 years (mean age: 41.36 ± 11.017 years). The Body Mass Index (BMI) of this group ranged from 17.26 to 35.51 kg/m², with an average of 24.379 ± 4.5078 kg/m². The average years of education were 11.57 ± 2.971 years, with a maximum of 21 years and a minimum of 7 years.
The control group also consisted of 50 males, with an average age of 41.66 ± 9.703 years (range: 26 to 64 years). The BMI in this group ranged from 17.57 to 37.03 kg/m², with an average of 24.4252 ± 3.8636 kg/m². The average years of education in the control group were 12.74 ± 3.28 years, with a maximum of 20 years and a minimum of 7 years.
Statistical analysis revealed no significant differences between the study and control groups in terms of age (t = -1.44, p = 0.885), BMI (t = -0.138, p = 0.89), and years of education (t = -1.95, p = 0.051) (all p-values > 0.05) (Table 1).
Table 1. Comparison of general characteristics between study and control groups.
3.2 Comparison of emotional state scores between the two groups
Analysis of the emotional states of the two groups revealed that the study group had significantly higher median scores on the PACS, BDI, and BAI scales compared to the control group. The median (interquartile range) scores for the study group were 12 (8, 17) for PACS, 13.5 (6, 21.25) for BDI, and 31 (24.75, 38) for BAI. In contrast, the control group had median scores of 3.5 (0, 6.25), 6 (3, 11.25), and 22.5 (21, 27) for PACS, BDI, and BAI, respectively. Statistical analysis indicated that the differences in PACS, BDI, and BAI scores between the study and control groups were significant (tPACS = -5.672, pPACS = 0.000,tBDI = -3.516, pBDI = 0.000, tBAI = -4.952, pBAI = 0.000), suggesting that patients in the acute withdrawal phase of AUD experienced more pronounced depression, anxiety, and alcohol craving compared to the healthy control group (p < 0.01). However, there was no significant difference in BIS scores between the two groups (p > 0.05).
Analysis of sleep quality between the two groups showed that 27 patients (54%) in the study group had a PSQI total score > 7, indicating significant sleep problems, compared to 10 patients (20%) in the control group. Further analysis of the PSQI dimensions revealed that patients in the study group had poorer subjective sleep quality, longer sleep latency, lower sleep efficiency, more sleep disturbances, higher use of sleep medication, and higher total PSQI scores compared to the control group, with statistically significant differences (p < 0.05) (Table 2).
Table 2. Comparison of emotional state and sleep factor scores between study and control groups (M [P25, P75]).
3.3 Analysis of factors affecting sleep quality in AUD patients during acute withdrawal
A multiple linear regression analysis was conducted on the study group, with sleep quality (total PSQI score) as the dependent variable. The independent variables included demographic data (age, BMI, age at first drink, and cumulative drinking duration) and scores from various assessment scales (PACS, BIS, BDI, BAI). This analysis aimed to identify which independent variables significantly impact sleep quality during the acute withdrawal phase in AUD patients.
3.3.1 Influence of general characteristics on sleep quality in AUD patients during acute withdrawal
The multiple linear regression model showed that there were no significant correlations between sleep quality and variables such as age, years of education, age at first drink, cumulative drinking duration, and BMI in AUD patients in acute withdrawal (p > 0.05) (Table 3).
Table 3. Regression analysis of clinical factors related to sleep quality.
3.3.2 Influence of emotional states on sleep quality in AUD patients during acute withdrawal
The multiple linear regression model showed that depression(b = 0.153, t = 2.68, p< 0.05), anxiety(b = 0.231, t = 3.69, p < 0.01), and alcohol craving(b = 0.215, t = 2.56, p < 0.05) were significantly higher in AUD patients during acute withdrawal compared to healthy controls, with all showing statistical significance (p < 0.05) (Table 4). These findings suggest that alcohol craving, depression, and anxiety may be potential factors contributing to poor sleep quality.
Table 4. Regression analysis of emotional factors related to sleep quality.
3.4 Comparison of various sleep monitoring indicators
3.4.1 Sleep quality analysis
Analysis of sleep quality between the two groups showed no significant difference in sleep onset latency (t = -1.037, p = 0.302) or the number of awakenings (t = -1.722, p = 0.088). However, compared to the control group, the study group exhibited significantly reduced sleep efficiency (t = 2.161, p = 0.033), decreased total sleep time (t = 2.612, p = 0.01) (Figure 1a), poorer sleep efficiency (t = 2.161, p = 0.033) (Figure 1b), increased proportion of snoring time (t = -3.44, p = 0.001) (Figure 1c), and a higher number of snoring events (t = -2.3, p = 0.021) (Figure 1d).
Figure 1. Comparison between the study group and the control group in various sleep quality indicators. (a) Comparison of the distribution of total sleep time in the study and control groups; (b) Comparison of sleep efficiency between study and control groups; (c) Comparison of proportion of snoring time between study and control groups; (d) Comparison of number of snoring events between study and control groups. **p < 0.01; *p < 0.05.
3.4.2 Sleep architecture analysis
The analysis of sleep architecture between the two groups showed a significant difference in the duration of REM sleep (t = 2.924, p = 0.004), with the study group having significantly less REM sleep compared to the control group.
When analyzing the different sleep stages, no significant differences were found in the duration of deep sleep (t = 1.729, p = 0.087), light sleep (t = 0.555, p = 0.58), or the proportions of these stages in total sleep time, including deep sleep percentage (t = 1.136, p = 0.259), light sleep percentage (t = -1.402, p = 0.164), and REM sleep percentage (t = 1.523, p = 0.131) (Table 5).
Table 5. Comparison of sleep architecture indicators ( ± s), M (P25, P75).
3.4.3 Analysis of AHI index and general vital signs during sleep
The AHI index refers to the average number of apnea and hypopnea events per hour of sleep, indicating the presence of sleep apnea and hypopnea.
Analysis of the AHI index between the two groups showed no significant differences in the average number of apnea and hypopnea events (t = -0.172, p = 0.863), suggesting no difference in sleep quality due to breathing problems between the groups.
Furthermore, analysis of general vital signs during sleep indicated no significant differences in the number of hypopnea events (t = -0.093, p = 0.926), number of apnea events (t = -0.345, p = 0.73), average heart rate (t = -0.77, p = 0.443), average oxygen saturation (t = -1.105, p = 0.272), or lowest oxygen saturation (t = -0.343, p = 0.733) between the two groups, suggesting that differences in general vital signs do not account for sleep quality differences (Table 6).
Table 6. Comparison of general vital signs during sleep ( ± s), M (P25, P75).
3.5 Correlation analysis of clinical psychological symptoms and sleep quality
3.5.1 Correlation between clinical psychological symptoms and sleep quality in the study group
Analysis of the quantified data of clinical psychological symptoms and sleep quality showed no significant correlation between sleep onset latency, total sleep time, sleep efficiency, and the number of awakenings with the total scores of emotional scales. However, there was a positive correlation between snoring time and PACS and BDI (r = 0.359, p < 0.05; r = 0.281, p < 0.05), and between the number of snoring events and BDI (r = 0.359, p < 0.01) (Table 7).
Table 7. Correlation analysis between clinical psychological symptoms and sleep quality.
3.5.2 Correlation between clinical psychological symptoms and sleep architecture in the study group
Analysis of the quantified data of clinical psychological symptoms and sleep architecture showed no significant correlation between light sleep, REM sleep, and the proportions of these stages with the total scores of emotional scales. However, there was a positive correlation between BAI and the duration of deep sleep (r = 0.310, p < 0.05), as well as the proportion of deep sleep (r = 0.305, p < 0.05) (Table 8).
Table 8. Correlation analysis between clinical psychological symptoms and sleep architecture.
3.5.3 Correlation between clinical psychological symptoms and AHI index and general vital signs in the study group
Analysis of the quantified data of clinical psychological symptoms, AHI index, and general vital signs showed no significant correlation between AHI, the number of hypopnea events, the number of apnea events, average oxygen saturation, and lowest oxygen saturation with the total scores of emotional scales. However, there was a positive correlation between BAI and average heart rate (r = 0.369, p < 0.01) (Table 9).
Table 9. Correlation analysis between clinical psychological symptoms and sleep process data.
4 Discussion
This study reveals significant issues in anxiety, depression, alcohol craving, and sleep disturbances among patients with AUD during acute withdrawal. Compared to non-drinkers, these patients exhibit markedly poorer sleep quality, sleep architecture, and related physiological indicators. Specifically, the total sleep time is significantly reduced, REM sleep duration and proportion are lower, and overall sleep efficiency is decreased in AUD patients. Our findings indicate a strong correlation between sleep disturbances and the severity of anxiety, depression, and alcohol craving in these patients—greater symptom severity is associated with poorer sleep quality.
Consistent with previous studies, we found that AUD patients in the acute withdrawal phase often experience significant anxiety and depression (59–61). These emotional disturbances are closely linked to the level of alcohol dependence during withdrawal (62). Importantly, these emotional issues and cravings for alcohol are key drivers of relapse in AUD patients (63). During acute withdrawal, relapse may alleviate emotional problems by modulating brain neurotransmitters (64). Chronic heavy drinking is known to cause emotional and cognitive disorders (65), and alcohol-related brain damage accounts for 10% of mild neurocognitive disorders (66). Although we observed emotional disturbances in alcohol withdrawal patients, further research is needed to understand the specific impact of drinking on emotions and to track the changes in emotional disturbances from drinking to withdrawal dynamically. Future studies should focus on the drinking population to explore the complex relationship between alcohol consumption and emotional disorders.
Using the PSQI, we found significant sleep disturbances among AUD patients in the acute withdrawal phase. This finding aligns with numerous previous studies showing widespread sleep problems during acute alcohol withdrawal (67, 68). However, the PSQI, being a subjective tool, has limitations. To objectively evaluate sleep conditions in AUD patients during acute withdrawal (69), we utilized PSG to analyze various physiological parameters and examine the relationship between specific sleep abnormalities and emotional problems. Compared to healthy controls, AUD patients in the acute withdrawal phase exhibited significantly more snoring time and frequency, which correlated with emotional disturbances. Previous studies have indicated that snoring during sleep increases the risk of depressive symptoms (70), and maternal snoring has been identified as a risk factor for prenatal depression (71). Notably, emotions also affect sleep (72). These findings support our observation that a bidirectional relationship may exist between sleep disturbances and mood disorders in AUD patients. However, research on the interaction between sleep and mood disorders in AUD populations remains relatively limited, highlighting the necessity for future studies in this field. Particularly noteworthy is that in-depth investigation into how sleep disturbances affect emotional states in AUD patients, and whether sleep improvement can effectively alleviate emotional problems in these patients, will hold significant clinical importance.
We also found significant differences in sleep architecture between AUD patients in the acute withdrawal phase and healthy controls, particularly in reduced REM sleep duration and proportion. Previous research has shown shortened REM latency and reduced REM sleep percentage during acute withdrawal. Our study aligns with George F. Koob et al.’s review (35), indicating that REM sleep decreases and recovery is limited during the acute withdrawal phase in AUD patients. REM sleep’s macro and microstructure are crucial for learning and memory consolidation (73), and alcohol withdrawal primarily affects the prefrontal cortex, striatum, and hippocampus functions, leading to cognitive dysfunction (74). Thus, reduced REM sleep during acute withdrawal may relate to persistent cognitive impairment and relapse risk.
It is important to note that AUD patients experience sleep problems during both heavy drinking and early remission, as well as during acute withdrawal (30, 75), mainly manifested as prolonged sleep latency and altered sleep structure (76). Analyzing sleep abnormalities in AUD patients during acute withdrawal suggests that these issues result from multiple factors (77), including physiological, psychological, and environmental influences.
Insomnia and emotional dysregulation in AUD patients are closely related to anxiety, post-traumatic stress disorder, and the severity of drinking (78). Emotional dysregulation and sleep disturbances have a complex bidirectional relationship. Anxiety and depression activate the HPA axis, which exacerbates sleep disorders, and the HPA axis itself is disrupted during alcohol withdrawal, leading to issues such as nighttime awakenings and prolonged sleep latency (79, 80). Poor sleep quality, in turn, increases stress and reduces emotional regulation, further worsening mood disorders (81). Additionally, alcohol withdrawal alters the central nervous system’s neurotransmitter systems, reducing inhibitory effects and increasing excitatory activity, which intensifies symptoms such as anxiety, depression, and sleep disturbances (82–85).
During withdrawal, increased alcohol cravings and accompanying depressive and anxious emotions lead to more pronounced sleep disturbances. The simultaneous presence of anxiety and emotional dysregulation may increase the risk of insomnia, while insomnia, in turn, may exacerbate emotional dysregulation and anxiety, though not all sleep disturbances are directly related to anxiety. Our study shows that AUD patients in the acute withdrawal phase have higher alcohol cravings and more pronounced depressive and anxious emotions, leading to more severe sleep disturbances. Insomnia itself can cause emotional dysregulation and anxiety, forming a self-perpetuating cycle. While not all sleep disturbances are directly linked to anxiety (86), we believe that alcohol withdrawal is a key initial factor causing sleep disturbances. Emotional issues (such as anxiety and depression) further negatively impact sleep quality, influenced by previous drinking levels and alcohol cravings. During withdrawal, alcohol-related sleep disturbances exacerbate overall sleep problems. This interaction suggests a complex relationship between alcohol withdrawal, emotional problems, and sleep disturbances.
This study underscores the critical interplay between emotional dysregulation, elevated craving, and impaired sleep architecture during acute alcohol withdrawal. Notably, reduced REM sleep emerges as a potential relapse predictor, emphasizing the therapeutic imperative of sleep restoration. PSG provides objective biomarkers to guide personalized interventions. Understanding these associations is crucial for developing effective clinical intervention strategies, particularly by integrating emotional regulation and sleep quality treatments to improve patient symptoms more comprehensively.
Our in-depth analysis recognizes several limitations. Firstly, although the study focuses on sleep problems and emotional disturbances during acute alcohol withdrawal, existing research has found a complex relationship between drinking behavior, sleep duration, and depressive symptoms (87). Evidence shows that AUD patients also experience these issues while drinking, which may worsen during withdrawal; however, we did not thoroughly explore the patients’ conditions during drinking. Moving forward, we should further investigate these issues during alcohol use to gain a deeper understanding of the relationship between alcohol consumption, sleep, and mood. Secondly, the study mainly assesses patients during the acute withdrawal phase without dynamically tracking sleep and emotional changes throughout the withdrawal process. Additionally, gender differences may play a significant role in the course of AUD, symptom presentation, and physiological and psychological responses during withdrawal (32), but this study only includes male patients, lacking data on female patients. Furthermore, the bidirectional relationship between insomnia, anxiety, and emotional dysregulation complicates constructing a comprehensive model to explain these interactions. The patients in the study quit smoking during hospitalization, while the complex relationship between smoking and sleep and emotional states (70) might confound withdrawal symptoms like anxiety, irritability, and sleep disturbances with alcohol withdrawal symptoms. We also acknowledge that certain personality factors (such as extraversion and openness) may have a modest influence on sleep quality (88). Additionally, low socioeconomic status (SES) has been linked to poor sleep quality, although the underlying mechanisms remain unclear (89). Although we used PSG for objective assessment, the limited sample size and short monitoring period may not fully capture long-term sleep problems. Finally, despite efforts to control environmental factors, the hospital environment itself, with fixed schedules, medical monitoring, and relative quietness, might impact patients’ sleep and emotions. Our research employed objective measures, such as PSG to systematically analyze sleep parameters during alcohol withdrawal, particularly changes in REM sleep, providing more precise data. Furthermore, our study highlighted the bidirectional relationship between sleep and emotional disturbances, a complex interaction that has not been thoroughly explored in the existing literature. Future research needs to more comprehensively understand and address sleep disturbances and emotional dysregulation in AUD patients, providing more effective clinical guidance and intervention strategies. The Charlson Comorbidity Index (CCI) is often used to assess comorbidities (90). While we excluded patients with major psychiatric disorders and substance dependence, conditions like liver disease or diabetes may still impact mood and sleep during alcohol withdrawal. Future studies should use the CCI and analyze the effects of comorbidities on mood and sleep in these patients.
5 Conclusion
Our study reveals patients with alcohol use disorder (AUD) in the acute withdrawal phase exhibit significant emotional disturbances and sleep problems. PSG is an effective tool for identifying these sleep issues in patients. Further analysis indicates a strong correlation between sleep quality and levels of depression, anxiety, and alcohol craving. Regular evaluation of sleep problems from both subjective and objective perspectives is beneficial in the treatment of AUD patients. Additionally, addressing emotional disturbances, anxiety, and sleep issues concurrently may enhance treatment outcomes for patients in the acute withdrawal phase, as these problems often interact and exacerbate each other. Therefore, an integrated approach that considers these factors to improve treatment efficacy is recommended.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving humans were approved by Shandong Mental Health Center, Shandong Jinan, PR China. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
XL: Data curation, Formal Analysis, Investigation, Software, Writing – original draft, Writing – review & editing. XK: Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing. XC: Data curation, Project administration, Supervision, Validation, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Acknowledgments
We sincerely thank all individuals and organizations who have supported this project.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Weafer J, Gorka SM, Dzemidzic M, Kareken DA, Phan KL, de Wit H. Neural correlates of inhibitory control are associated with stimulant-like effects of alcohol. Neuropsychopharmacology. (2021) 46:1442–50. doi: 10.1038/s41386-021-01014-5
2. Charness ME. Brain lesions in alcoholics. Alcohol Clin Exp Res. (1993) 17:2–11. doi: 10.1111/j.1530-0277.1993.tb00718.x
3. Osna NA, Donohue TM Jr., Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. (2017) 38:147–61.
4. Ishak KG, Zimmerman HJ, Ray MB. Alcoholic liver disease: pathologic, pathogenetic and clinical aspects. Alcohol Clin Exp Res. (1991) 15:45–66. doi: 10.1111/j.1530-0277.1991.tb00518.x
5. Rumgay H, Murphy N, Ferrari P, Soerjomataram I. Alcohol and cancer: epidemiology and biological mechanisms. Nutrients. (2021) 13(9):3173. doi: 10.3390/nu13093173
6. Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. (2019) 394:781–92. doi: 10.1016/S0140-6736(19)31775-1
7. Substance Abuse and Mental Health Services Administration (US); Office of the Surgeon General (US). Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. Washington (DC): US Department of Health and Human Services; November 2016.
8. Zhang R, Wiers CE, Manza P, Tomasi D, Shokri-Kojori E, Kerich M, et al. Severity of alcohol use disorder influences sex differences in sleep, mood, and brain functional connectivity impairments. Brain Commun. (2022) 4:fcac127. doi: 10.1093/braincomms/fcac127
9. Jakubczyk A, Trucco EM, Klimkiewicz A, Skrzeszewski J, Suszek H, Zaorska J, et al. Association between interoception and emotion regulation in individuals with alcohol use disorder. Front Psychiatry. (2019) 10:1028. doi: 10.3389/fpsyt.2019.01028
10. O’Daly OG, Trick L, Scaife J, Marshall J, Ball D, Phillips ML, et al. Withdrawal-associated increases and decreases in functional neural connectivity associated with altered emotional regulation in alcoholism. Neuropsychopharmacology. (2012) 37:2267–76. doi: 10.1038/npp.2012.77
11. Bandura A, Caprara GV, Barbaranelli C, Gerbino M, Pastorelli C. Role of affective self-regulatory efficacy in diverse spheres of psychosocial functioning. Child Dev. (2003) 74:769–82. doi: 10.1111/cdev.2003.74.issue-3
12. Trevisan LA, Boutros N, Petrakis IL, Krystal JH. Complications of alcohol withdrawal: pathophysiological insights. Alcohol Health Res World. (1998) 22:61–6.
13. Carlson RW, Kumar NN, Wong-Mckinstry E, Ayyagari S, Puri N, Jackson FK, et al. Alcohol withdrawal syndrome. Crit Care Clin. (2012) 28:549–85. doi: 10.1016/j.ccc.2012.07.004
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders FeA. VA: American Psychiatric Association (2013).
15. Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, et al. The American psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. (2018) 175:86–90. doi: 10.1176/appi.ajp.2017.1750101
16. Gallus S, Lugo A, Borroni E, Vignoli T, Lungaro L, Caio G, et al. Symptoms of protracted alcohol withdrawal in patients with alcohol use disorder: A comprehensive systematic review. Curr Neuropharmacol. (2023) 21:409–16. doi: 10.2174/1570159X20666220706105253
17. De Soto CB, O’Donnell WE, Allred LJ, Lopes CE. Symptomatology in alcoholics at various stages of abstinence. Alcohol Clin Exp Res. (1985) 9:505–12. doi: 10.1111/j.1530-0277.1985.tb05592.x
18. Jung ME, Metzger DB. Alcohol withdrawal and brain injuries: beyond classical mechanisms. Molecules. (2010) 15:4984–5011. doi: 10.3390/molecules15074984
19. Freeman CR, Wiers CE, Sloan ME, Zehra A, Ramirez V, Wang GJ, et al. Emotion recognition biases in alcohol use disorder. Alcohol Clin Exp Res. (2018) 42(8):1541–7. doi: 10.1111/acer.13802
20. Heilig M, Egli M, Crabbe JC, Becker HC. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol. (2010) 15:169–84. doi: 10.1111/j.1369-1600.2009.00194.x
21. Steinig J, Foraita R, Happe S, Heinze M. Perception of sleep and dreams in alcohol-dependent patients during detoxication and abstinence. Alcohol Alcohol. (2011) 46:143–7. doi: 10.1093/alcalc/agq087
22. Bell S, Britton A, Kubinova R, Malyutina S, Pajak A, Nikitin Y, et al. Drinking pattern, abstention and problem drinking as risk factors for depressive symptoms: evidence from three urban Eastern European populations. PloS One. (2014) 9:e104384. doi: 10.1371/journal.pone.0104384
23. Harper KM, Knapp DJ, Todd CA, Balan I, Aurelian L, Criswell HE, et al. Phenotyping CCL2 containing central amygdala neurons controlling alcohol withdrawal-induced anxiety. Front Cell Neurosci. (2020) 14:580583. doi: 10.3389/fncel.2020.580583
24. Glover EJ, Starr EM, Chao Y, Jhou TC, Chandler LJ. Inhibition of the rostromedial tegmental nucleus reverses alcohol withdrawal-induced anxiety-like behavior. Neuropsychopharmacology. (2019) 44:1896–905. doi: 10.1038/s41386-019-0406-8
25. Rassnick S, Heinrichs SC, Britton KT, Koob GF. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. (1993) 605:25–32. doi: 10.1016/0006-8993(93)91352-S
26. Dao NC, Suresh Nair M, Magee SN, Moyer JB, Sendao V, Brockway DF, et al. Forced abstinence from alcohol induces sex-specific depression-like behavioral and neural adaptations in somatostatin neurons in cortical and amygdalar regions. Front Behav Neurosci. (2020) 14:86. doi: 10.3389/fnbeh.2020.00086
27. Uzbay TI. Atypical antipsychotic drugs and ethanol withdrawal syndrome: a review. Alcohol Alcohol. (2012) 47:33–41. doi: 10.1093/alcalc/agr142
28. Freeman K, Brureau A, Vadigepalli R, Staehle MM, Brureau MM, Gonye GE, et al. Temporal changes in innate immune signals in a rat model of alcohol withdrawal in emotional and cardiorespiratory homeostatic nuclei. J Neuroinflamm. (2012) 9:97. doi: 10.1186/1742-2094-9-97
29. Jiang X, Lin Q, Xu L, Chen Z, Yan Q, Chen L, et al. Indoleamine-2,3-dioxygenase mediates emotional deficits by the kynurenine/tryptophan pathway in the ethanol addiction/withdrawal mouse model. Front Cell Neurosci. (2020) 14:11. doi: 10.3389/fncel.2020.00011
30. Chakravorty S, Chaudhary NS, Brower KJ. Alcohol dependence and its relationship with insomnia and other sleep disorders. Alcohol Clin Exp Res. (2016) 40:2271–82. doi: 10.1111/acer.2016.40.issue-11
31. Chaudhary NS, Kampman KM, Kranzler HR, Grandner MA, Debbarma S, Chakravorty S. Insomnia in alcohol dependent subjects is associated with greater psychosocial problem severity. Addict Behav. (2015) 50:165–72. doi: 10.1016/j.addbeh.2015.06.021
32. Jones MR, Brandner AJ, Vendruscolo LF, Vendruscolo JCM, Koob GF, Schmeichel BE. Effects of alcohol withdrawal on sleep macroarchitecture and microarchitecture in female and male rats. Front Neurosci. (2022) 16:838486. doi: 10.3389/fnins.2022.838486
33. Palmer CA, Oosterhoff B, Bower JL, Kaplow JB, Alfano CA. Associations among adolescent sleep problems, emotion regulation, and affective disorders: Findings from a nationally representative sample. J Psychiatr Res. (2018) 96:1–8. doi: 10.1016/j.jpsychires.2017.09.015
34. Haario P, Rahkonen O, Laaksonen M, Lahelma E, Lallukka T. Bidirectional associations between insomnia symptoms and unhealthy behaviours. J Sleep Res. (2013) 22:89–95. doi: 10.1111/j.1365-2869.2012.01043.x
35. Koob GF, Colrain IM. Alcohol use disorder and sleep disturbances: a feed-forward allostatic framework. Neuropsychopharmacology. (2020) 45:141–65. doi: 10.1038/s41386-019-0446-0
36. Crum RM, Ford DE, Storr CL, Chan YF. Association of sleep disturbance with chronicity and remission of alcohol dependence: data from a population-based prospective study. Alcohol Clin Exp Res. (2004) 28:1533–40. doi: 10.1097/01.ALC.0000141915.56236.40
37. Laniepce A, Cabé N, André C, Bertran F, Boudehent C, Lahbairi N, et al. The effect of alcohol withdrawal syndrome severity on sleep, brain and cognition. Brain Commun. (2020) 2:fcaa123. doi: 10.1093/braincomms/fcaa123
38. Jafari B, Mohsenin V. Polysomnography. Clin Chest Med. (2010) 31:287–97. doi: 10.1016/j.ccm.2010.02.005
39. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med. (2017) 13:479–504. doi: 10.5664/jcsm.6506
40. Harrison EI, Roth RH, Lobo JM, Kang H, Logan J, Patel SR, et al. Sleep time and efficiency in patients undergoing laboratory-based polysomnography. J Clin Sleep Med. (2021) 17:1591–8. doi: 10.5664/jcsm.9252
41. Rundo JV, Downey R 3rd. Polysomnography. Handb Clin Neurol. (2019) 160:381–92. doi: 10.1016/B978-0-444-64032-1.00025-4
42. Angarita GA, Emadi N, Hodges S, Morgan PT. Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review. Addict Sci Clin Pract. (2016) 11:9. doi: 10.1186/s13722-016-0056-7
43. Afonso Romano C, Neves Martins S, Amaral J.. Alcohol use disorder and sleep disturbances: Current perspectives. European Psych. (2023) 66(S1):S141. doi: 10.1192/j.eurpsy.2023.353
44. Goldstein AN, Walker MP. The role of sleep in emotional brain function. Annu Rev Clin Psychol. (2014) 10:679–708. doi: 10.1146/annurev-clinpsy-032813-153716
45. Gujar N, Yoo SS, Hu P, Walker MP. Sleep deprivation amplifies reactivity of brain reward networks, biasing the appraisal of positive emotional experiences. J Neurosci. (2011) 31:4466–74. doi: 10.1523/JNEUROSCI.3220-10.2011
47. Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of antidepressants on sleep. Curr Psychiatry Rep. (2017) 19:63. doi: 10.1007/s11920-017-0816-4
48. Cederlöf E, Holm M, Taipale H, Tiihonen J, Tanskanen A, Lähteenvuo M, et al. Antipsychotic medications and sleep problems in patients with schizophrenia. Schizophr Res. (2024) 267:230–8. doi: 10.1016/j.schres.2024.03.015
49. Grinchii D, Dremencov E. Mechanism of action of atypical antipsychotic drugs in mood disorders. Int J Mol Sci. (2020) 21(24):9532. doi: 10.3390/ijms21249532
50. Vetulani J, Nalepa I. Antidepressants: past, present and future. Eur J Pharmacol. (2000) 405:351–63. doi: 10.1016/S0014-2999(00)00565-3
51. Landry MJ, Smith DE, Steinberg JR. Anxiety, depression, and substance use disorders: diagnosis, treatment, and prescribing practices. J Psychoactive Drugs. (1991) 23:397–416. doi: 10.1080/02791072.1991.10471611
52. Conroy DA, Arnedt JT. Sleep and substance use disorders: an update. Curr Psychiatry Rep. (2014) 16:487. doi: 10.1007/s11920-014-0487-3
53. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. (1988) 56:893–7. doi: 10.1037/0022-006X.56.6.893
54. Luty J, O’Gara C. Validation of the 13-Item Beck Depression Inventory in alcohol-dependent people. Int J Psychiatry Clin Pract. (2006) 10:45–51. doi: 10.1080/13651500500410117
55. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. (1995) 51:768–74. doi: 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1
56. Ko YY, Fang SC, Huang WC, Huang MC, Chang HM. Validation of the Chinese version of penn alcohol craving scale for patients with alcohol use disorder. Psychiatry Investig. (2024) 21:159–64. doi: 10.30773/pi.2022.0217
57. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. (1989) 28:193–213. doi: 10.1016/0165-1781(89)90047-4
58. Agnew HW Jr., Webb WB, Williams RL. The first night effect: an EEG study of sleep. Psychophysiology. (1966) 2:263–6. doi: 10.1111/j.1469-8986.1966.tb02650.x
59. Blanchard RJ, Magee L, Veniegas R, Blanchard DC. Alcohol and anxiety: ethopharmacological approaches. Prog Neuropsychopharmacol Biol Psychiatry. (1993) 17:171–82. doi: 10.1016/0278-5846(93)90041-P
60. Nielsen B, Andersen K. Alcohol, anxiety, and depression. Ugeskr Laeger. (2022) 184(14):V10210816.
61. Petit G, Luminet O, Maurage F, Tecco J, Lechantre S, Ferauge M, et al. Emotion regulation in alcohol dependence. Alcohol Clin Exp Res. (2015) 39:2471–9. doi: 10.1111/acer.2015.39.issue-12
62. Shen G, Yang S, Wu L, Chen Y, Hu Y, Zhou F, et al. The oxytocin receptor rs2254298 polymorphism and alcohol withdrawal symptoms: a gene-environment interaction in mood disorders. Front Psychiatry. (2023) 14:1085429. doi: 10.3389/fpsyt.2023.1085429
63. Ralston TE, Palfai TP, Rinck M. The influence of depressed mood on action tendencies toward alcohol: the moderational role of drinking motives. Addict Behav. (2013) 38:2810–6. doi: 10.1016/j.addbeh.2013.07.013
64. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. (2010) 35:217–38. doi: 10.1038/npp.2009.110
65. Dvorak RD, Sargent EM, Kilwein TM, Stevenson BL, Kuvaas NJ, Williams TJ. Alcohol use and alcohol-related consequences: associations with emotion regulation difficulties. Am J Drug Alcohol Abuse. (2014) 40:125–30. doi: 10.3109/00952990.2013.877920
66. Gutwinski S, Schreiter S, Priller J, Henssler J, Wiers CE, Heinz A. Drink and think: impact of alcohol on cognitive functions and dementia - evidence of dose-related effects. Pharmacopsychiatry. (2018) 51:136–43. doi: 10.1055/s-0043-118664
67. Huitron-Resendiz S, Nadav T, Krause S, Cates-Gatto C, Polis I, Roberts AJ. Effects of withdrawal from chronic intermittent ethanol exposure on sleep characteristics of female and male mice. Alcohol Clin Exp Res. (2018) 42:540–50. doi: 10.1111/acer.2018.42.issue-3
68. Reid-Varley WB, Ponce Martinez C, Khurshid KA. Sleep disorders and disrupted sleep in addiction, withdrawal and abstinence with focus on alcohol and opioids. J Neurol Sci. (2020) 411:116713. doi: 10.1016/j.jns.2020.116713
69. Engstrøm M, Rugland E, Heier MS. Polysomnography (PSG) for studying sleep disorders. Tidsskr Nor Laegeforen. (2013) 133:58–62. doi: 10.1037/bul0000053
70. Ashare RL, Lerman C, Tyndale RF, Hawk LW, George TP, Cinciripini P, et al. Sleep disturbance during smoking cessation: withdrawal or side effect of treatment? J Smok Cessat. (2017) 12:63–70. doi: 10.1017/jsc.2016.11
71. O’Brien LM, Owusu JT, Swanson LM. Habitual snoring and depressive symptoms during pregnancy. BMC Pregnancy Childbirth. (2013) 13:113. doi: 10.1186/1471-2393-13-113
72. Vandekerckhove M, Weiss R, Schotte C, Exadaktylos V, Haex B, Verbraecken J, et al. The role of presleep negative emotion in sleep physiology. Psychophysiology. (2011) 48:1738–44. doi: 10.1111/j.1469-8986.2011.01281.x
73. Roehrs T, Roth T. Drug-related sleep stage changes: functional significance and clinical relevance. Sleep Med Clin. (2010) 5:559–70. doi: 10.1016/j.jsmc.2010.08.002
74. Lukoyanov NV, Madeira MD, Paula-Barbosa MM. Behavioral and neuroanatomical consequences of chronic ethanol intake and withdrawal. Physiol Behav. (1999) 66:337–46. doi: 10.1016/S0031-9384(98)00301-1
75. Popovici I, French MT. Binge drinking and sleep problems among young adults. Drug Alcohol Depend. (2013) 132:207–15. doi: 10.1016/j.drugalcdep.2013.02.001
76. Thakkar MM, Sharma R, Sahota P. Alcohol disrupts sleep homeostasis. Alcohol. (2015) 49:299–310. doi: 10.1016/j.alcohol.2014.07.019
77. Brower KJ. Assessment and treatment of insomnia in adult patients with alcohol use disorders. Alcohol. (2015) 49:417–27. doi: 10.1016/j.alcohol.2014.12.003
78. Fairholme CP, Nosen EL, Nillni YI, Schumacher JA, Tull MT, Coffey SF. Sleep disturbance and emotion dysregulation as transdiagnostic processes in a comorbid sample. Behav Res Ther. (2013) 51:540–6. doi: 10.1016/j.brat.2013.05.014
79. Becker HC. Effects of alcohol dependence and withdrawal on stress responsiveness and alcohol consumption. Alcohol Res. (2012) 34:448–58.
80. Nicolaides NC, Vgontzas AN, Kritikou I, Chrousos G. HPA Axis and Sleep. In: Endotext. South Dartmouth (MA): MDText.com, Inc. (2000).
81. Baglioni C, Nanovska S, Regen W, Spiegelhalder K, Feige B, Nissen C, et al. Sleep and mental disorders: A meta-analysis of polysomnographic research. Psychol Bull. (2016) 142:969–90. doi: 10.1037/bul0000053
82. Glue P, Nutt D. Overexcitement and disinhibition. Dynamic neurotransmitter interactions in alcohol withdrawal. Br J Psychiatry. (1990) 157:491–9. doi: 10.1192/bjp.157.4.491
83. Oh J, Petersen C, Walsh CM, Bittencourt JC, Neylan TC, Grinberg LT. The role of co-neurotransmitters in sleep and wake regulation. Mol Psychiatry. (2019) 24:1284–95. doi: 10.1038/s41380-018-0291-2
85. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. (2008) 69 Suppl E1:4–7.
86. Hasler BP, Soehner AM, Clark DB. Sleep and circadian contributions to adolescent alcohol use disorder. Alcohol. (2015) 49:377–87. doi: 10.1016/j.alcohol.2014.06.010
87. Kim Y, Kim J, Oh JW, Lee S. Association between drinking behaviors, sleep duration, and depressive symptoms. Sci Rep. (2024) 14:5992. doi: 10.1038/s41598-024-56625-x
88. Hintsanen M, Puttonen S, Smith K, Törnroos M, Jokela M, Pulkki-Råback L, et al. Five-factor personality traits and sleep: evidence from two population-based cohort studies. Health Psychol. (2014) 33:1214–23. doi: 10.1037/hea0000105
89. Philbrook LE, Saini EK, Fuller-Rowell TE, Buckhalt JA, El-Sheikh M. Socioeconomic status and sleep in adolescence: The role of family chaos. J Fam Psychol. (2020) 34:577–86. doi: 10.1037/fam0000636
Keywords: alcohol use disorder, polysomnography, sleep disorder, acute withdrawal, mood disorder
Citation: Liu X, Kong X and Chen X (2025) Investigation and analysis of factors related to sleep conditions during the acute withdrawal period of alcohol use disorder. Front. Psychiatry 16:1469324. doi: 10.3389/fpsyt.2025.1469324
Received: 23 July 2024; Accepted: 14 April 2025;
Published: 06 May 2025.
Edited by:
Mauro Ceccanti, Sapienza University of Rome, ItalyReviewed by:
Devon Hansen, Washington State University, United StatesRan Wang, The First Hospital of Hebei Medical University, China
Copyright © 2025 Liu, Kong and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xu Chen, Y2g5OWpuQDE2My5jb20=
†These authors have contributed equally to this work and share first authorship